2004
Targeted Therapy in Breast Cancer The HER-2/neu Gene and Protein
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Targeted Therapy in Breast Cancer The HER-2/neu Gene and Protein. Molecular & Cellular Proteomics 2004, 3: 379-398. PMID: 14762215, DOI: 10.1074/mcp.r400001-mcp200.Peer-Reviewed Original ResearchConceptsBreast cancerNeu statusHormonal therapyAdvanced metastatic breast cancerHER-2/neu oncogeneHER-2/neu statusNew hormonal therapiesSerum-based testingMale breast cancerMetastatic breast cancerBreast cancer specimensClinical breast cancer specimensNeu gene amplificationEpidermal growth factor receptorTransmembrane tyrosine kinase receptorPrediction of responseGrowth factor receptorTyrosine kinase receptorsTrastuzumab therapyDuctal carcinomaNeu overexpressionHER-2Targeted therapyTumor cytosolsDisease outcome
2003
HER-2/neu testing in breast cancer.
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Hortobagyi GN. HER-2/neu testing in breast cancer. American Journal Of Clinical Pathology 2003, 120 Suppl: s53-71. PMID: 15298144, DOI: 10.1309/949fpq1aq3p0rlc0.Peer-Reviewed Original ResearchConceptsBreast cancerNeu testingNeu statusProspective clinical outcome studyTrastuzumab-based therapyMajor clinical trialsEarly clinical stagePredictors of responseClinical outcome studiesBreast cancer specimensAdvanced diseaseClinical responseClinical stageClinical trialsStandards of practiceCancer specimensImmunohistochemical analysisOutcome studiesPotential efficacyCancerSitu hybridization techniqueRecent evidenceTherapySitu hybridization methodExcellent resultsThe HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy. The Oncologist 2003, 8: 307-325. PMID: 12897328, DOI: 10.1634/theoncologist.8-4-307.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiomarkers, TumorBreast NeoplasmsBreast Neoplasms, MaleCombined Modality TherapyEducation, Medical, ContinuingFemaleGene Expression Regulation, NeoplasticGenes, erbB-2Genetic Predisposition to DiseaseHumansIncidenceMaleMiddle AgedNeoplasm StagingPrognosisRisk AssessmentSensitivity and SpecificitySurvival AnalysisTrastuzumabTreatment OutcomeConceptsBreast cancerHER-2/neu statusHER-2/neu oncogeneNeu geneNew hormonal therapiesSerum-based testingMale breast cancerHER-2/neu geneTarget of therapyNeu gene amplificationEpidermal growth factor receptorTransmembrane tyrosine kinase receptorPrediction of responseGrowth factor receptorHormonal therapyTyrosine kinase receptorsTrastuzumab therapyDuctal carcinomaNeu overexpressionHER-2Disease outcomeTumor cytosolsTherapy responseNeu statusNeu testing